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VIRAL CAUSES OF GASTROENTERITIS IN THE ERA OF WIDESPREAD 
ROTAVIRUS VACCINATIONS. Dame Idossa, Novagrami George, and Virginia Pierce 
(Sponsored by Marietta Vázquez). Department of Pediatrics, Yale University, School of 
Medicine, New Haven, CT.  
 
Background: It is unknown if widespread use of Rotavirus (RV) vaccine will impact the 
primary causative agent of viral gastroenteritis (VGE).  
Objective: To identify changes in epidemiology of VGE affected by vaccination, 
determine factors associated with higher severity of illness, and assess agreeability 
between two clinical severity-grading scales; Clark and Vesikari.  
Methods: We analyzed fecal samples of children, 6 months-5 years of age, evaluated at 
YNHH for VGE. Fecal samples were tested using a real-time PCR assay. Primer and 
probe sequences targeted conserved regions of the genome for RV, Norovirus GI/GII, 
Adenovirus, Astrovirus, and Sapovirus. Data were analyzed using SPSS.  
Results: Of the 268 fecal samples analyzed, 215 (80%) were positive for at least one 
viral pathogen. Of those, 133 (62%) had a single viral pathogen identified and 82 (38%) 
had multiple pathogens. The frequencies of pathogens were: RV in 132 (61%), Norovirus 
GI/GII in 93 (43%), Astrovirus in 32 (15%), Adenovirus in 24 (11%), and Sapovirus in 
21 (10%). For subjects <12 months of age the frequency of viral pathogens were: RV 48 
(41%), Norovirus GI/GII 41(35%), Astrovirus 12 (10%), Adenovirus 10 (9%), and 
Sapovirus 7 (6%). State of being infected by any pathogen, having educated caretakers, 
infection with RV, and not being vaccinated for RV were associated with greater severity 
of diarrheal illness. In contrast, difference in severity of illness seen with Hispanic 
ethnicity, Black race, and coinfection with multiple pathogens was not statistically 
significant. Lastly, Clark and Vesikari clinical severity grading scales were shown to 
have poor agreeability (k=0.309), which was not improved by modification.  
Conclusions: We conclude that in the era of widespread use of RV vaccine, the 
epidemiology of VGE may be changing. We’ve identified several factors that may be 
associated with higher severity of illness, which may help guide clinicians in improving 
care and directing resources. Lastly, we confirm the poor agreeability between the Clark 
and Vesikari scales, which may guide future researchers to standardize use of clinical 
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Diarrheal illnesses are one of the most common causes of morbidity and mortality in 
children worldwide. Acute diarrhea accounts for 2 to 3 million deaths per year with most 
occurring in young children in developing countries [1]. Each year in the United States, 
gastroenteritis is responsible for approximately 600,000 outpatient medical visits, 55 to 
70,000 hospitalizations, and 20 to 60 deaths [2, 3]. The costs associated with diarrheal 
illnesses are also very high with total annual direct and indirect costs of approximately $1 
billion [4-6]. Below we review the literature on the epidemiology, risk factors, and 
clinical severity grading scales for gastroenteritis, with particular attention to viral 
gastroenteritis.  
 
Type of Pathogens Causing Gastroenteritis: Parasitic, Bacterial and Viral 
The causes of acute diarrhea in children vary depending on multiple factors such as 
location, season, and population studied. The infections responsible for causing 
gastroenteritis in children can be divided into parasitic, bacterial, and viral infections.  
 
Parasitic causes of diarrhea are not as common in developed countries as they are in the 
developing world, however, they still account for 1% to 8% of cases of diarrhea in 
pediatric patients. In the United States, Giardia and Cryptosporidium infections are the 
most common parasitic causes of disease [7]. They are usually acquired via fecal to oral 
transmission. Most community-wide epidemics have resulted from a contaminated water 
supply. Person to person transmission can also occur, most commonly in daycare centers. 




Bacterial pathogens are the second most common cause of gastroenteritis in pediatric 
patients in developed countries, accounting for 2% to 10% of cases [7]. The most 
common species include Salmonella, Shigella, and Campylobacter. Other notable 
bacteria also includes enterohemorrhagic Escherichia coli (EHEC) and with the 
increasing use of antibiotics, Clostridium difficile, although this tends to be uncommon in 
the pediatric population [7]. With proper management, the prognosis for bacterial 
gastroenteritis tends to be very good, especially in developed countries. Mortality is 
usually due to dehydration and malnutrition from a protracted course.  
 
Viral pathogens are by far the most common cause of diarrheal illnesses in the United 
States, accounting for 75-90% of pediatric gastroenteritis [8]. Before initiation of the RV 
vaccination program in 2006, nearly every child in the United States was infected with 
RV by age 5 years; the majority had gastroenteritis, resulting in significant morbidity and 
mortality [2]. Other viruses also known to cause gastroenteritis include Norovirus, 
Adenovirus, Astrovirus, and Sapovirus. Transmission for all of these viruses is presumed 
to be fecal to oral. The morbidity and mortality associated with viral gastroenteritis has 
significantly decreased since the initiation of RV vaccination program. The effectiveness 
of the RV vaccine is consistent with clinical trials estimates [9]. Studies from the United 
States, Europe, and Australia have demonstrated effectiveness of up to 100% (95% CI 
85%-100%) associated with decreased hospitalizations for RV gastroenteritis. Healthcare 
utilization (hospitalizations and emergency-department visits) was also reduced by up to 
90% [10, 11]. Although the efficacy of RV vaccine is reduced in developing countries, 




Latin America, RV vaccine has resulted in a 17–51% reduction in gastroenteritis- 
associated hospitalizations and 59–81% reduction in RV hospitalization among children 
younger than five years of age [12].  
 
Characteristics of Viral Agents  
Below we review characteristics of the following viruses that were examined in this 
study: Rotavirus (RV), Norovirus, Sapovirus, Adenoirus, and Astrovirus.  
 
RV is a double-stranded RNA virus, in the family of Reoviridae, which is classified into 
various groups, subgroups, and serotypes. There are at least 15 different serotypes of RV; 
presently, 5 serotypes of RV (G1, G2, G3, G4, and G9) account for the majority of the 
strains circulating worldwide. Surface antigens VP7 (G protein) and VP4 (P protein) are 
2 important structural viral proteins involved in eliciting the immune response through 
neutralizing antibodies. Rotaviruses have substantial diversity, with a possible 132 
separate G-P combinations [3]. This great diversity of serotypes and surface antigens 
creates an opportunity for multiple assortment and combination of RV serotypes, 
allowing for the potential emergence of new serotypes of the virus.  
 
Caliciviruses are a family of single-stranded, nonenveloped RNA viruses. The two 
recognized genera that cause diarrheal disease in humans are noroviruses (Norwalk-like 
viruses) and sapoviruses (Sapporo-like viruses). Sapoviruses have the typical calicivirus 
morphology that on electron microscopy reveals the “Star of David” appearance, similar 




normally does not reveal the “Star of David” appearance. Noroviruses are known as 
“small round structured viruses” [13]. Both Noroviruses and Sapoviruses are genetically 
diverse, and multiple strains with distinct genetic identities circulate within a community 
at the same time. In the Norovirus genus, the GII strains have been found to be more 
common than the GI strains worldwide [14, 15].  
 
Human adenoviruses (HAdVs) are classified in the family Adenoviridae, genus 
Mastadenovirus, which contains seven known species, from A to G [16]. They are 
double-stranded, linear, nonenveloped DNA viruses. To date there are over 60 distinct 
serotypes known to cause human infections. Adenoviruses are known to cause many 
types of illnesses including respiratory, ocular, and urinary tract infection [17]. The most 
common serotypes that are associated with gastroenteritis are 40, 41, and, to a lesser 
extent, 31 [7].  
 
Astrovirus is a nonenveloped, single-stranded RNA viruses with a characteristic starlike 
appearance by electron microscopy. Eight human antigenic types are currently known. 
Astroviruses have a worldwide distribution and multiple antigenic types are known to co-
circulate in the same region [18]. 
 
Introduction of Rotavirus Vaccine Program  
In 1998, RotaShieldR, a rhesus RV tetravalent vaccine became the first RV vaccine to be 
licensed in the United States. Unfortunately, it was recalled shortly after its licensure due 




back for RV vaccination program [3]. After several years, two different vaccines were 
developed, licensed, and approved for use by the US Food and Drug Administration. 
RotateqR (RV5) is a pentavalent human-bovine reassortant live-attenuated oral vaccine 
licensed in 2006; and RotarixR (RV1) is a monovalent live-attenuated human strain 
vaccine, licensed in 2008, which shares neutralizing epitopes against the most common 
RV serotypes. Universal RV vaccination was recommended for U.S. infants by the 
Advisory Committee on Immunization Practices (ACIP) in February of 2006. 3 doses of 
the pentavalent RV vaccine [RV5], RotaTeqR (Merck and Company) were to be given at 
ages 2, 4, and 6 months [2, 3]. Since the initiation of this widespread RV vaccination, the 
number RV cases and its complications in the United States have been significantly 
reduced[19, 20]. Studies from middle and low income countries have also seen many 
improvements, including reduction of VGE associated mortality of 22-41% [12].  
 
Clinical Severity Grading Systems 
The Vesikari and Clark clinical severity scales were developed and routinely used to 
assess severity of cases and assist in investigations of diarrhea and dehydration in RV 
vaccine clinical trials.  
 
The Vesikari clinical severity grading system (VSS) is a 20-point scale that is classified 
into two categories (non-severe and severe) [21]. Scores greater than or equal to 11 are 
considered severe [22]. The Clark clinical severity grading system (CSS) is a 24-point 
scale that is classified into three categories (mild, moderate and severe) [23]. Scores less 




points severe [22]. Both severity scales assess clinical information, such as the magnitude 
and duration (in days) of diarrhea and vomiting, and the maximum temperature during 
illness. In addition to these parameters, the Clark scale assesses the magnitude and 
duration of behavioral symptoms such as irritability and lethargy, and the duration of a 
temperature greater than 38.0°C, whereas the Vesikari scale assesses dehydration and 
treatment (rehydration or hospitalization) [22]. 
 
Several studies have concluded that the Clark scale is less likely to identify a disease as 
severe, compared with the Vesikari Clinical Severity Scoring System [24]. Thus it tends 
to have a less sensitive measure of severity of illness. This is because among the five 
common items included in both scoring systems (# of stools/day, duration of diarrhea, # 
of emesis/day, duration of emesis, rectal temperature), the Vesikari scale provided a 
higher score for each item compared to the Clark scale, with the exception of temperature 
[25]. Thus higher value is reached with a lower frequency of episodes or number of days 
of duration with the Vesikari scale, resulting in greater proportion of cases being 






STATEMENT OF PURPOSE  
Since the initiation of the RV vaccine program in 2006, cases of severe gastroenteritis 
have significantly decreased [2]. Nevertheless, diarrheal illness and complication 
associated with them still account for thousands of outpatient/ED visits and 
hospitalization [8]. The current distribution pattern of viral pathogens causing pediatric 
gastroenteritis in era of widespread RV vaccination program still remains unknown. Is 
the RV still the most common cause or have other viral pathogens, such as astrovirus or 
norovirus taken its place?  
 
Understanding the current pathogenic distribution of viral pathogens is of great 
importance to improving care for infants and children who suffer from diarrheal illness. 
There have been many studies that explore the viral causes of gastroenteritis, both in 
developed and developing countries [1, 13-16, 26-28]. There have also been several 
studies of active surveillance of certain viruses such as RV, post vaccination program [3, 
11, 29]. However, there haven’t been many studies that explore the epidemiology of viral 
pathogens known to cause gastroenteritis in the era of wide spread RV vaccination. This 
study will seek to identify any changes, if any, in the distributive pattern of viral 
gastroenteritis, since the initiation of widespread use of the RV vaccine.  
 
Specific Aim 1: To identify any changes in the epidemiology of viral gastroenteritis. 
Hypothesis #1: We predict that RV will still be responsible for causing viral 
gastroenteritis in notable portion of children <5 years of age. However, we predict it will 




Other viral pathogens, notably Norovirus, will likely take its place.  
 
Specific Aim 2: To determine factors associated with higher severity of illness as graded 
by Clark and Vesikari Clinical Severity Scales.  
Hypothesis #2: We predict that having infected status, Hispanic ethnicity, Black race, 
lower education status of carers of child, infection with RV, no vaccination for RV, and 
infection with multiple pathogens will be associated with greater severity of illness. 
 
Specific Aim 3: To determine the agreeability between the clinical severity grading 
systems in children seen at Yale New Haven Hospital (Emergency department and 
inpatient units).  
Hypothesis #3: We predict that there will be poor agreeability between the Clark and 






MATERIALS AND METHODS  
Participants Selection Process 
Eligible children were prospectively enrolled into match-controlled study of RV vaccine 
effectiveness in children (6 months – 5 years of age) at Yale-New Haven Children’s 
Hospital in New Haven, Connecticut January 2010 through June 2011. Eligible children 
were those who met all the following criteria:  
1) Presented to the hospital with acute gastroenteritis (≥3 looser-than-normal stools 
in a 24 –hour period during the illness, and onset of diarrhea ≤ 10 days at 
presentation). 
2) Diarrhea as the main or one of the main reasons for the visit and managed as an 
emergency department (ED) patient or inpatient.  
3) Eligible to have received at least one RV1 or RV5 dose ≥14 days before 
presentation.  
4) Lived in the usual catchment area of the hospital.  
 
Children with immunocompromising condition such as a malignancy or HIV infection 
were not eligible, because this made them ineligible from receiving the RV vaccines. 
After informed consent was obtained, a standardized questionnaire was administered to 
the parent/guardian (which queried demographics, symptoms, name and location of all 
immunization providers, and general household information) and a stool sample was 
collected. Children were classified as either a RV case or a “RV-negative” gastroenteritis 
control based on the RV antigen enzyme immunoassay result. The study was in 




Subjects were interviewed to collect clinical and demographic information. Medical 
records were reviewed to assess previous vaccination with RV vaccine and to assess 
clinical severity of disease using both the Clark and Vesikari clinical severity scales. 
Enrollment was performed approximately 40 hours per week and included evening and 
weekend periods. The project was approved by the institutional review boards the 
hospital and reviewed for human subjects protection at CDC.  
 
Study Design 
We conducted a retrospective cohort study using leftover frozen stool samples from a 
previous study that were sent to Children’s Hospital of Philadelphia (CHOP) to be tested 
for the presence of viral stool pathogen known to cause VGE such as RV, Adenovirus, 
Astrovirus, Sapovirus, and Norovirus using a new real-time PCR assay, developed by the 
collaborators at CHOP.   
 
Procedure 
A total of 293 frozen specimens [stool samples or diaper lining soaked in viral transport 
medium (VTM)] from pediatric patients were tested.  All samples had been previously 
characterized as either positive (n = 93) or negative (n = 200) for RV by RV-specific 
enzyme immunoassay, conducted as part of the case-control investigation by the CDC. 
Each stool specimen (both RV positive and negative specimens) was rapidly thawed in a 
37oC water bath and then prepared as a 5% suspension in 1.0 ml of nuclease free water, 
vigorously vortexed for 30 sec, and clarified by centrifugation at maximum speed for 5 




Real-time PCR Assays 
Nucleic acids were extracted from 200 µl of each clinical specimen (prepared 5% stool 
suspension supernatant or VTM-soaked diaper lining) by standard procedures using the 
MagNA Pure LC automated instrument (Roche Diagnostics, Indianapolis, IN) and 
corresponding Roche total nucleic acid isolation kit.  Extracted product was heated to 
95oC for 5 min and then immediately placed in ice for 1 min.  Individual real-time PCR 
assays were performed in 50-µl volumes on a 7500 real-time PCR system (Applied 
Biosystems, Foster City, CA) using 5 µl of eluted nucleic acid; universal master mixes 
for either RNA (Ambion AgPath-ID One-Step RT-PCR master mix; Applied Biosystems) 
or DNA (TaqMan universal master mix; Applied Biosystems); universal amplification 
conditions consisting of 1 cycle for 10 min at 45°C and 1 cycle for 10 min at 95°C, 
followed by 45 two-step cycles of 15 s at 95°C and 45 s at 45°C; and TaqMan 
fluorogenic chemistry for detection.   Positive and negative controls were processed with 
each batch of clinical specimens from extraction of nucleic acids through the detection of 
amplified products.  Negative controls consisted of 1.0 x 106 cells/ml of an uninfected 
human lung carcinoma cell line (A549 cells; ATCC CCL-185), and positive controls 
were prepared as a mixture of clinical material from previously positive patients.  No-
template controls were included in each reaction plate for all sets of primers and probes.  
Primer and probe sequences targeted conserved regions of the genome for each virus 
(Table 1) and were based on the published literature for Adenovirus types 40 and 41[30], 
Astrovirus [31], Norovirus genogroups I and II [32], RV [30], and Sapovirus [33].  
Specimens and controls were considered positive when the generated fluorescence signal 




the threshold before 38 cycles were considered positive without further testing, and those 
that reached the threshold at or after 38 cycles but before the last of 45 cycles were 
considered positive only if, upon duplicate repeat testing of separate aliquots of stored 







Table 1.  Nucleotide sequences of real-time PCR primers and probesa 
Primers and 
probes 
Nucleotide sequences (5’-3’) Gene target 
Adenovirus 40 and 41 
Forward TTC CAG CAT AAT AAC TCW GGC TTT G 
Hexon Reverse AAT TTT TTC TGW GTC AGG CTT GG 
Probeb (FAM)-CCW TAC CCC CTT ATT GG-(MGBNFQ) 
Astrovirus 
Forward CCD GCC AGR CTC ACA GAA GAG 
Capsid protein 
precursor 
Reverse GAC TTG CTA GCC ATC ACA CTY C 
Probec (FAM)-ACT CCA TCG-(ZEN)-CAT TTG GAG GGG AGG 
ACC-(IABkFQ) 
Norovirus genogroups I and II 
Genogroup I 
forward 





CTT AGA CGC CAT CAT CAT TYA C 
Genogroup I probe 
A 
(FAM)-AGA TYG CGA TCY CCT GTC CA-(TAMRA) 
Genogroup I probe 
B 
(FAM)-AGA TCG CGG TCT CCT GTC CA-(TAMRA) 
Genogroup II 
forward 
CAR GAR BCN ATG TTY AGR TGG ATC AG 
Genogroup II 
reverse 
TCG ACG CCA TCT TCA TTC ACA 
Genogroup II probe (VIC)-TGG GAG GGC GAT CGC AAT CT-(TAMRA) 
Rotavirus 
Forward 1 GGA TGT CCT GTA CTC CTT GTC AAA A 
Inner capsid 
protein VP6 
Forward 2 GGA GGT TCT GTA CTC ATT GTC AAA AA 
Reverse 1 TCC AGT TTG GAA CTC ATT TCC A 
Reverse 2 TCC AGT TTG AAA GTC ATT TCC ATT 
Probe 1 (FAM)-ATA ATG TGC CTT CGA CAA T-(MGBNFQ) 
Probe 2 (FAM)-AAT ATA ATG TAC CTT CAA CAA T-(MGBNFQ) 
Sapovirus 




Forward 2 TTG GCC CTC GCC ACC TAC 
Reverse CCC TCC ATY TCA AAC ACT AWT TTG 
Probe (FAM)-TGG TTY ATA GGY GGT AC-(MGBNFQ) 
 
aAbbreviations:  FAM, 6-carboxyfluorsescein; MGBNFQ, minor groove binder/non-fluorescent quencher; 
VIC, proprietary formulation, Applied Biosystems; IABkFQ, Iowa Black FQ quencher, proprietary 
formulation, Applied Biosystems; TAMRA, 6-carboxytetramethylrhodamine.  International Union of 
Biochemistry base codes:  W = A or T, D = A or G or T, R = A or G, Y = C or T, B = C or G or T, N = A 
or C or G or T.  
bLogan et al. used two probes; we used one probe with mixed bases. cWe incorporated an internal ZEN 




Resolution of Discordant Results  
When there was discordance between real-time PCR and enzyme immunoassay result, 
the real-time PCR assay was repeated again using the original sample.  If the initial real-
time PCR result was positive and one or both of the duplicate retests were positive, the 
final PCR result was reported as positive.  Conversely, if the initial real-time PCR result 
was negative and one or both of the duplicate retests were negative, the final PCR result 




Out of the 293 samples, 18 were duplicates (2 samples collected from same subject). In 1 
of the 9 subjects with duplicate samples, one sample was collected from a diaper lining 
and the other was collected from a whole stool. In another 3 of the 9 subjects, both 
samples were collected from a diaper lining, but were collected on different days. There 
was 1 subject in which both samples were from a whole stool, but were collected on 2 
different days. In these 5 subjects with duplicate samples, the PCR result for the two 
samples gave different results. Thus these 10 samples (from 5 subjects with discordant 
results) were omitted from the final analysis. The remaining 4 subjects had a PCR results 
that were the same for both of their samples. Because they had a total of 8 samples, 4 of 
those samples were omitted from the final analysis to insure that each subject’s sample 
was only counted once. The 11 Rota only samples were also omitted in order not to skew 
the results towards RV. These were samples tested by EIA and known to have only RV. 
This left 268 samples (293-10 discordant-4duplicate-11rota only) to be included in the 






Data were analyzed with SPSS 14.0 software for Windows. Categorical data were 
analyzed using the χ2 test. Continuous variables were analyzed using the t-test procedure. 
Cohen kappa statistics used to measure the agreement between the two severity scoring 
scales by adjusting both scales to have the same number of categories. A P-value of 
<0.05 was considered significant. 
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Pierce MD, our collaborator from CHOP conducted the real-time PCR for all of the 
samples and detailed out the methods that were used to do this. This researcher 
performed the statistical analysis for all of the data. Dame Idossa, Novagrami George, BS 









Table 2 presents an overview of the social, demographic, insurance status, parental 
education, prematurity, and vaccination status of the 268 analyzed subjects. Overall, 
participants were approximately 18 months of age at intake (M=18.12, SD 12.2) and 
predominately comprised of males (61.2%). Almost half of the participants (47%)  
 
TABLE 2.  Characteristics for N=268 Subjects     
Characteristics Total Cases  





Age at Intake (months)    
     Mean (SD) 18.12 (12.2) 18.03 (11.9) 15.72 (12.6) 
     Median 16 16 13 
Gender    
     Male  164 (61.2% 137 (63.7%) 27 (50.1%) 
     Female 104 (38.8%) 78 (36.3%) 26 (49.1%) 
Ethnicity    
     Hispanic/Latino 127 (47.4%) 99 (46.0%) 28 (52.8%) 
     Non Hispanic/Latino 141 (52.6%) 116 (54.0%) 25 (47.2%) 
Race    
     White 114 (42.5%) 94 (43.7%) 20 (37.7%) 
     Black 57 (21.3%) 44 (20.5%) 13 (24.5%) 
     American Indian 3 (1.1%) 3 (1.40%) 0 (0%) 
     Asian 8 (3.0%) 4 1.86%) 4 (7.5%) 
     Other 84 (31.3%) 67 (31.2%) 17 (32.1%) 
Insurance    
     Private 78 (29.1%) 70 (32.6%) 8 (15.1%) 
     Public 182 (67.9%) 138 (64.2%) 44 (84.9%) 
     None 8 (3.0%) 7 (3.26%) 1 (1.9%) 
Parental education level    
     <High school 67 (25%) 51 (23.7%) 16 (30.2%) 
     High school/GED 123 (45.9%) 96 (44.7%) 27 (50.1%) 
     College 50 (18.7%) 44 (20.5%) 6 (11.3%) 
     Graduate 28 (10.4%) 24 (11.2%) 4 (7.5%) 
Prematurity    
     Full term 233 (86.9%) 187 (87.0%) 46 (86.8%) 
     Premature 35 (13.1%) 28 (13.0%) 7 (13.2%) 
Vaccinations    
     Rota 195 (72.8%) 148 (68.8%) 47 (88.7%) 
     Tdap + other vax 266 (99.2%) 213 (99.1%) 53 (100%) 
     Unknown  2 (.75%) 2 (.93%) 0 
Clinical Severity score    
     Mean Clark Clinical Severity scale 10.90 ± 3.4  11.13 ± 3.4 10.09 ± 3.4 




identified as Hispanic/Latino ethnicity. 42.5% of the participants identified as Caucasian,  
with the rest identifying as Black (21.3%), American Indian (1.1%), Asian (3.0%), and 
other (31.3%). The majority of the participants had health insurance coverage through 
public (67.9%) or private (29.1%) institutions. A quarter of the parents of participants had 
less than a high school level of education with the rest having high school diploma/GED 
(45.9%), College degree (18.7%) or Graduate degree (10.4%). Most of the children were 
born at full term (86.9%) and had received RV vaccine (72.8%) and other childhood 
vaccines (99.2%). The mean clinical severity score as determined by the Clark scale was 
10.9 ± 3.4 and by Vesikari scale was 10.38 ± 3.6. The stratified characteristics for the 
participants infected with any pathogen and for those not infected with any tested 
pathogen were also similar and as listed in Table 2. 
 
Pathogens and Severity 
 
Tables 3, 4, and 5 describe the pathogens detected in subjects who were infected. Of the 
215 infected subjects, 133 (49.5%) were single infections and 82 (30.6%) were multiple 
infections. Overall, Adenovirus was detected in 24 (11.2%), Astrovirus in 32 (14.9%), 
Norovirus GI in 4 (1.9%), Norovirus GII in 89 (41.4%), RV in 132 (61.4%), and 
Sapovirus in 21 (9.8%) of the participants.  
  
Of the 215 infected participants, RV caused the greatest severity of illness as measured 
by the Clark Clinical Severity scale 11.7 ± 3.4, followed by Adenovirus, Norovirus GII, 
Astrovirus, Sapovirus, and Norovirus GI (Table 3). However, Adenovirus caused the 




followed by RV, Norovirus GII, Astrovirus, sapovirus, and lastly Norovirus GI, as shown 
in Table 3.  
TABLE 3.  Pathogens Detected in Infected subjects    
Pathogens Detected Total Cases 





Adenovirus 24 (11.2) 11.5 (3.1) 12 (3.4) 
Astrovirus 32 (14.9) 10.2 (3.2) 9.44 (3.9) 
Norovirus GI 4 (1.9) 8.8 (4.5) 7.25 (3.6) 
Norovirus GII 89 (41.4) 10.9 (3.3) 10.66 (3.4) 
Rotavirus 132 (61.4) 11.7 (3.4) 11 (3.6) 
Sapovirus 21 (9.8) 9.5 (2.7) 9.19 (3.4) 
    
* Total adds up to > 215 because 82 subjects were coinfected with multiple pathogens and hence counted >1 times 
Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe” 
 
 
Single Viral Infections 
 
Of the 133 subjects infected with a single virus, 8 (6%) were infected by Adenovirus, 8 
(6%) by Astrovirus, 42 (32%) by Norovirus GII, 66 (50%) by RV, and 9 (7%) by 
Sapovirus. In these subjects, Adenovirus caused the greatest severity of illness as 
measured by the Clark Clinical Severity scale 12.1 ± 3.7, followed by RV, Norovirus GII, 
Astrovirus, and Sapovirus (Table 4). However, RV caused the greatest severity of illness 
as measured by the Vesikari Clinical Severity scale 12.5 ± 3.3, followed by Adenovirus, 
Norovirus GII, Astrovirus, Sapovirus, as shown in Table 4.  
 
TABLE 4.  Pathogens Detected in Single Infections    
Pathogens Detected Total Cases 





Adenovirus 8(6) 12.1 (3.7) 10.4 (2.1) 
Astrovirus 8(6) 8.6 (2.8) 9.6 (2.4) 
Norovirus GI - - - 
Norovirus GII 42(32) 10.1 (3.1) 10.1 (3.3) 
Rotavirus 66(50) 11.6 (3.6) 12.5 (3.3) 
Sapovirus 9(7) 8.2 (2.3) 8.6 (3.2) 
    








Multiple Viral Infections 
 
Of the 82 subjects who were co-infected by multiple viruses, 15 (18.3%) were infected by 
Adenovirus, 26 (31.7%) by Astrovirus, 4 (4.9%) by Norovirus GI, 49 (59.8%) by 
Norovirus GII, 71 (86.6%) by RV, and 12 (14.6%) by Sapovirus. In these subjects, 
Adenovirus caused the greatest severity of illness as measured by the Clark Clinical 
Severity scale 12.3 ± 3.5, followed by Norovirus GII, RV, Astrovirus, Sapovirus and 
Norovirus GI (Table 5). Similarly Adenovirus caused the greatest severity of illness when 
measured by the Vesicari Clinical severity score 12.1 ± 3.5, followed by Norovirus GII, 
RV, Sapovirus, Astrovirus, and Norovirus GI (Table 5).   
 
TABLE 5.  Pathogens Detected in Multiple Infections    
Pathogens Detected Total Cases 





Adenovirus 15(18.3) 12.33 (3.5) 12.13 (3.5) 
Astrovirus 26(31.7) 10.42 (3.4) 9.54 (4.2) 
Norovirus GI 4(4.9) 8.75 (5.2) 7.25 (4.1) 
Norovirus GII 49(59.8) 11.61 (3.3)  11.24 (3.5) 
Rotavirus 71(86.6) 11.14 (3.4) 10.51 (3.5) 
Sapovirus 12(14.6) 10.17 (2.4) 9.92 (4.1) 
    
* Total adds up to > 82 because all of these subjects were coinfected with multiple pathogens 
Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe” 
 
 
Pathogens by Age 
 
When we stratified participants by age, the children between 0-12 months of age were 
most commonly infected by RV 48 (40.7%), followed by Norovirus GII 40 (33.9%), 
Astrovirus 12 (10.2%), Adenovirus 10 (8.5%), Sapovirus 7 (5.9%), and Norovirus GI 1 
(0.85%). This trend was similar for children between 12-24 months and 24-36 months. 
For children who were ≥ 36 months of age, RV 8 (72.7%) caused the majority of the 




infections detected in this age group. Adenovirus and Norovirus GI did not cause any 
infections (Table 6).   
 
TABLE 6.  Pathogens by Age     
Pathogens Detected 0-12 mo 
N= 118 (%) 
12-24 mo 
N= 122 (%) 
24-36 mo 
N= 57 (%) 
36+ mo 
N= 11 (%) 
Adenovirus 10 (8.5) 9(7.4) 4 (7) 0 
Astrovirus 12 (10.2) 15 (12.3) 6 (10.5) 1 (9.1) 
Norovirus GI 1 (.85) 0 3 (5.3) 0 
Norovirus GII 40 (33.9) 38 (31.1) 11 (19.3) 1 (9.1) 
Rotavirus 48 (40.7) 53 (43.4) 47.4) 8 (72.7) 
Sapovirus 7 (5.9) 7 (5.7) 6 (10.5) 1 (9.1) 
     
* Total adds up to > 264 because of coinfections  
 
 
RV Vaccination Status’ Effects on Infection With Pathogens and Severity of Illness 
 
Of the 268 participants, 195 (72.8%) were vaccinated against RV with at least one dose 
of RotateqR or RotarixR vaccine. In these participants, RV was the most common viral 
pathogen detected 83 (38.4%), followed by Norovirus GII 73 (33.8%), Astrovirus 27 
(12.5%), Sapovirus 16 (7.4%), Adenovirus 13 (6.02%), and Norovirus GI 4 (1.85). 
Adenovirus had the highest severity of illness when measured using the Clark Clinical 
Severity scale 11.5 ± 2.8, followed by RV, Norovirus GII, Astrovirus, Sapovirus, and 
Norovirus GI (Table 7). Adenovirus also caused the greatest severity of illness as 
measured by the Vesikari Clinical Severity scale 11.9 ± 3.6, followed by Norovirus GII, 









TABLE 7.  Pathogens Detected in Rotavirus Vaccinated Participants  




Adenovirus 13 (6.0) 11.54 (2.8) 11.92 (3.6) 
Astrovirus 27 (12.5) 9.82 (3.1) 9.18 (4.2) 
Norovirus GI 4 (1.9) 8.87 (4.5) 7.25 (3.6) 
Norovirus GII 73 (33.8) 10.52 (3.2) 10.52 (3.3) 
Rotavirus 83 (38.4) 10.73 (3.1) 9.87 (3.2) 
Sapovirus 16 (7.4) 9.56 (2.8) 9 (3.6) 
 
* Total adds up to > 195 because of coinfections  
Clark: <9 “mild”, 9-16 “moderate”, >16 “severe” Vesikari: Scores <11 “non severe”, ≥11 “severe” 
 
Of the 73 (27.2 %) participants who were not vaccinated with at least one dose of 
RotateqR or RotarixR vaccine, RV was the most common viral pathogen detected 48 
(58.5%), followed by Norovirus GII 15 (18.3%), Adenovirus 11 (13.4%), Astrovirus and 
Sapovirus both detected in 4 (4.9%) of the stool samples. Norovirus GI did not cause any 
infections in these participants. RV caused the greatest severity of illness as measured by 
the Clark Clinical Severity scale 13.4 ± 3.0, followed by Astrovirus, Norovirus GII, 
Adenovirus, and Sapovirus (Table 8). Conversely, Astrovirus caused the greatest severity 
of illness as measured by the Vesikari Clinical Severity scale 13.3 ± 2.1, followed by RV, 
Adenovirus, Norovirus GII, and Sapovirus (Table 8).  
 
TABLE 8.  Pathogens Detected Rotavirus Non Vaccinated Participants 




Adenovirus 11 (13.4) 11.45 (3.5) 12.09 (3.1) 
Astrovirus 4 (4.9) 13.25 (2.5) 13.25 (2.1) 
Norovirus GI 0 Na Na 
Norovirus GII 15 (18.3) 12.67 (3.6) 11.33 (3.8) 
Rotavirus 48 (58.5) 13.44 (3.0) 12.98 (3.3) 
Sapovirus 4 (4.9) 9.75 (2.4) 10.75 (2.3) 
 
* Total adds up to > 73 because of coinfections  









Factors Associated with Higher Severity of Illness 
 
We explored various factors that may be associated with higher severity of illness using 
T-test. Both the Clark and Vesikari severity scales were used to measure severity. Table 9 
depicts the p values of the various characteristics tested. 
 
State of being infected by any pathogen, having educated caretakers (some college or 
greater level of education), infection with RV, and not being vaccinated for RV were 
associated with greater severity of illness. In contrast, having multiple infections, being 
of Hispanic ethnicity and being of Black race were not associated with greater severity of 
illness (Table 9).  
	
Table	9.	Factors	association	with	Severity of Illness	
Characteristics Mean CSS P-value 
CSS 
Mean VSS P-value 
VSS 
Non Vaccinated vs Vaccinated 12.59 vs 10.31 <0.001 12.29 vs 9.70 <0.001 
Rotavirus vs non Rotavirus 12.53 vs 9.88 <0.001 11.64 vs 9.88 0.002 
Rotavirus vs Norovirus GII 12.53 vs 10.00 <0.001 11.64 vs 10.00 0.013 
Rotavirus vs Sapovirus 12.53 vs 8.55 0.001 11.64 vs 8.22 0.006 
Rotavirus vs Astrovirus 12.53 vs 9.63 0.018 11.64 vs 8.63 0.023 
≤HS diploma vs >HS diploma 10.75 vs 11.70 0.035 9.83 vs 12.05 <0.001 
Infected vs non Infected 11.13 vs 10.09 0.047 10.65 vs 9.25 0.011 
Rotavirus vs Adenovirus 12.53 vs 10.38 0.076 11.64 vs 12.13 0.718 
Black vs non Black race 10.67 vs 11.59 0.100 10.25 vs 11.34 0.062 
Public vs Private Insurance 10.85 vs 11.54 0.130 9.88 vs 11.76 <0.001 
Non Hispanic vs Hispanic 10.71 vs 11.00 0.668 10.65 vs 9.25 0.011 
Single vs Multiple Infections 11.14 vs 10.74 0.944 11.11 vs 10.55 0.741 
	
 
Agreeability Between Vesikari and Clark Severity Scales 
 
Figure 1 shows all cases (N=268) graded by both the Vesikari and Clark severity grading 
scales individually (Panels A and B). The Clark Severity Scale was modified into a 2 




Clark scale was then compared to the Vesikari Scale as in shown in panel C. Lastly the 
Vesikari scale was modified into a 3-category system by regrouping into mild, moderate, 
and severe groups. This modified Vesikari scale was compared the original scale as 
shown in panel D. 
 
 
Figure 1. Agreeability of Clark and Vesikari Severity Grading Scales 
 
A and B show cases as graded by Vesikari and Clark scale respectively. C shows cases as graded by 
Vesikari and modified 2-category Clark scale. D shows cases as graded by Clark and modified 3-category 
Vesikari scale. Blue=Clark, Red=Vesikari.  
 
The comparison between the two scoring scales cannot be analyzed statistically because 
the distribution categories are not even. The Clark scale is divided into 3 ranges (<9, 9–
16 and >16) while the Vesikari scale is divided into 2 ranges only (<11 and ≥11). Thus 
we modified Clark scale into a 2-category scale and the Vesikari into a 3-category scale 




agreeability between the Clark and Vesikari severity grading scales. Kappa values can 
range from -1 to 1. Values <1 suggest poor agreement, 0-0.20 slight agreement, 0.21-0.40 
fair agreement, 0.41-0.60 moderate agreement, 0.61-0.8 substantial agreement, and 0.81-
1 almost perfect agreement. As depicted in Table 10, the Kappa scores for the original 
and modified Vesikari and Clark scales show there is slight or fair agreement at best 
between the two grading systems.	 	
 
Table 10.  Agreeability between Vesikari and Clark grading systems 
Type of scale Kappa value 95%CI P-value 
Original .306 (0.218,0.394) <0.001 
Modified Clark .111 (0.050-0.172 <0.001 









RV vaccines have significantly reduced the burden of RV disease both in the United 
States and globally. Studies in the United States have shown a decline of approximately 
85% to 95% in RV cases during the 2008 season compared with previous seasons [2]. In 
addition, data from the Natural Respiratory and Enteric Virus Surveillance System 
(NREVSS), network of U.S. laboratories that provide the CDC with weekly reports of the 
number of tests performed and positive results obtained for a variety of pathogens, have 
shown a >50% decrease of RV positive samples in 2007–2008 season of RV when 
compared to the season of 1991–2006 [29]. Studies from developing countries have 
shown lower efficacy of the vaccine; nonetheless, great reductions in severe diarrheal 
illness in children who received the RV vaccine. For example, studies from Bangladesh 
and Vietnam have shown the vaccine to be 48% efficacious against severe disease in 
young infants [35, 36]. RV vaccine has undoubtedly reduced the mortality and morbidity 
associated with viral gastroenteritis in young children.  
 
There have also been studies that have demonstrated a shift in the seasonality of RV since 
initiation of RV vaccine [37]. In addition, the usual spread of RV associated 
gastroenteritis from southwest to northeast has not been shown post RV vaccine 
initiation. The RV season has also been noted to be later in the year, shorter, and less 
pronounced when compared to pre-vaccination era [29]. All of this information suggests 
that the morbidity and mortality associated with RV gastroenteritis is increasingly 





Interesting results in regards to distribution of pathogens post RV vaccination program 
have emerged from our study. Overall, our data shows RV remains the most common 
cause of both single and co-infections causing viral gastroenteritis in children in CT. 
Given the successes of the RV vaccination program [38], this is unexpected, although not 
surprising. There are many different types of the RV serotypes and surface antigens [39]. 
This great diversity of serotypes and surface antigens creates an opportunity for multiple 
assortment and combination of RV serotypes, allowing for the potential emergence of 
new serotypes of the virus. The current vaccines available cannot protect against all of 
the possible RV serotypes or any new serotypes that emerge.  
 
In subjects who were previously vaccinated for RV, the frequency of RV infection was 
significantly decreased, as expected (38%), and we have noted the frequency of 
Norovirus GII has increased (34%). The data from those who were not vaccinated for RV 
seems to be similar to data from pre RV vaccination era, with RV accounting for nearly 
60% of the viral gastroenteritis. In this group Norovirus GII is found to cause only 18% 
of disease. An interesting result from this study is the change in the frequency of 
Norovirus infections when the data were stratified by ages. Norovirus GII frequency is 
increased mostly in the children <12months, who are the target population for RV 
vaccination programs. This may suggests this trend may be a direct result of RV being 
better controlled in this age group. A recent active surveillance study, since the 
introduction of RV vaccines, found that Norovirus has become the leading cause of 
medically attended acute gastroenteritis in U.S. children and is associated with nearly 1 




Norovirus is >$270 million and expected to continue rising [40]. Given the recent 
advances in the development of candidate Norovirus vaccines [27, 41], the need to 
determine the burden of gastroenteritis associated with Norovirus and other viruses is 
increasingly more important.  
 
 
Several factors associated with increased severity of illness emerged from our study. 
Primarily, the detection of any viral pathogen tested was associated with greater severity 
of illness as expected. Subjects who exhibited symptoms of viral gastroenteritis but did 
not shed any of the viruses tested could have been infected with parasitic, bacterial, or 
viral agents that were not tested for. Regardless, these subjects had less severe disease 
manifestations than their viral infected counterparts. As predicted subjects who were not 
vaccinated against RV had a greater severity of illness (P=<0.001) (regardless of what 
pathogen they were infected with) when compared to those that were vaccinated against 
RV. We also found, higher education of status of caretakers was found to be associated 
with higher severity of illness as measured by both Clark (11.70 p=0.035) and Vesikari 
((12.05 p=<0.001) Scale. Given the usual association of higher level of education with 
higher annual income and, typically, better access to care/better health outcomes, this 
result was unexpected. A possible explanation for this could be that caretakers with 
higher level of education could potentially have more demanding jobs and presumably 
present their child to the ED/hospital at later or more severe stages of disease. This could 
result in detection or ascertainment bias.  Lastly, subjects who were infected with RV, as 




expected. Other studies have also shown that RV associated gastroenteritis cause the 
greatest severity of illness in children <5 years old [42, 43]. 
 
Health disparities in the United States are pervasive and present in almost all realms of 
medicine. In primary care, minority children are more likely to receive poorer quality of 
care in terms of provider interactions, preventive services and management of common 
conditions [44]. However, contrary to our hypothesis, the results of this study did not 
support his fact. Hispanic ethnicity did not result in higher severity of illness, in fact non-
Hispanics were found to have greater severity of illness only by the Vesikari scale 
(p=<0.001). The difference in severity measured by the Clark Scale was found to be not 
statistically significant (p=0.095). Black race was also not associated with greater 
severity of illness, when measured by both the Clark (p=0.100) and Vesikari (p=0.062) 
scale. Lastly, subjects with public insurance were also not found to have higher severity 
of illness. In fact, subjects with private insurance were found to have a greater severity of 
illness as measure only by the Vesikari scale (p=<0.001). The data from this study did not 
demonstrate disparities in severity of illness among minority or poor participants. 
 
Interestingly, being infected with more than one pathogen also did not result in greater 
severity of illness as predicted. In fact our data demonstrated the difference between 
severity of illness of those with single and multiple infections was not statistically 





As predicted the Clark and Vesikari severity grading systems had poor agreeability even 
with modification of the scales. The results obtained using the two severity scales differ 
significantly and can disrupt comparisons [25]. The original scales were found to have 
only fair agreement as measured by the kappa score. When the Clark three-category scale 
was transformed into a two-category scale by combining mild and moderate categories as 
non-severe, the agreeability actually worsened. Modifying the Vesikari two-category 
scale into a three-category scale by further subdividing the severe category into two parts, 
provided a better correlation between the two severity scales, but still did not achieve a 
good level of agreement. This suggests that there either needs to be a development of a 
new severity grading system or standardized use of only one of the existing scales in 




There are several limitations of this study. The greatest limitation is our choice of 
modality for detecting pathogens in the stool samples. The real time PCR assay was 
designed to detect sequences of conserved regions of the genome for RV, Norovirus 
GI/GII, Adenovirus, Astrovirus, and Sapovirus. Thus other viral pathogens, if present, 
would not be detected via this method. However, previous studies support the notion that 
the selected viral agents are known to cause the majority of viral gastroenteritis in the 
United States and worldwide [30-32, 45, 46] Additionally, the real time PCR does not 
detect other causative agents of gastroenteritis such as bacteria or parasitic agents. The 
subjects who were exhibiting symptoms of gastroenteritis, but did not show infection by 
the tested pathogens likely had infection with bacterial, parasitic, or other viral 




possibility that some viruses that are seen in the other months were not fully accounted 
for in our study. Lastly, there were some samples that were omitted from the study due to 
differing PCR results. There are a number of reasons why the PCR results for two 
different samples from the same subject might give different results. Primarily, the timing 
of sample collection is important. Samples obtained on different days are more likely to 
give different results. Secondly, the sample type is also important. Stool vs. diaper lining 
squeezed out into viral transport medium (which dilutes the specimen) is more likely to 
give different results. In addition, the samples could have had low viral load. One test 
might be positive and the other negative in different samples if the PCR target was 
present in only very small amounts. Lastly, there is always the possibility of 
contamination of the sample and problems with the sample quality/specimen handling. 
These are some possible reasons for why we had these samples from the same subject 
produce different PCR results.  
 
Clinical implications  
 
Currently, there are no studies that identify the epidemiological changes in the causative 
pathogens of VGE in post the widespread RV vaccination programs. Based on results 
from our study, we conclude that in the era of widespread use of RV vaccine, the most 
common agent causing VGE at YNH children's hospital still remains RV. Norovirus 
frequency seems to be increasing, mostly in the younger children who are the target 
population for RV vaccination program. This suggests the epidemiology of VGE may 
indeed be changing as more children are protected from RV. We’ve identified several 
factors that may be associated with higher severity of illness, which may help guide 




agreeability between the Clark and Vesikari scales, which may guide future researchers 
to standardize use of clinical severity scales.   
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